Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Related RGEN
Wednesday's After-Hours Movers: 10 Stocks To Watch
Events for the Week of Nov. 17-21, 2014
Related PFE
Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
Trans Pacific Trade Pact Finally Agreed
Fund Managers Like These Dividend Stocks: Should You? (Investor's Business Daily)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA


Related Articles (RGEN + PFE)

Get Benzinga's Newsletters